Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing ...
New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line SEATTLE, Wash. & VENLO, ...
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. The Caris Assure® platform is a ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
RNA library preparation can make or break whole transcriptome sequencing data acquisition. Speed, sensitivity, and scalability are key workflow considerations, but researchers often face bottlenecks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results